The father of the dominant theory of Alzheimer’s disease told another eminent researcher he is “causing harm” by criticizing ...

Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to ...

A survey of 1700 Americans 45 and older found that 79% would want to know if they were in the early stages of Alzheimer's.

In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

SEATTLE — There's new hope for people in the early stages of Alzheimer's disease. A new medication called donanemab appears ...

A Neurologist Answers Questions Patients Might Have about the New Alzheimer’s Drug Lecanemab What a patient and family members can expect from the recently approved drug lecanemab—and what ...

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with early-stage disease.

A team of scientists, including researchers from University College London (UCL), has discovered key differences in how four ...

Lecanemab is indicated for adult patients ... represented good continued sequential growth. Kisunla (donanemab) is used to treat adults with early symptomatic Alzheimer’s disease (AD), which ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early ...

Eisai Co., Ltd. and Biogen Inc. announced that the European Commission has granted marketing authorization for lecanemab, marketed as Leqembi®, making it the first therapy in the EU to target an ...